<p>8-hydroxyefavirenz (ng/mL) and efavirenz/8-hydroxyefavirenz ratio (MR) was compared between patients who developed concomitant efavirenz-based HAART and rifampicin based anti-tubercular drugs induced liver injury (cases) and those who did not (controls).</p
The aim of this study was to determine the utility of dried blood spots (DBS) compared with conventi...
INTRODUCTION: A recent report described a possible interaction between tenofovir (TFV) and efavirenz...
The steady-state pharmacokinetics of efavirenz and nevirapine, when used in combination to treat hum...
(See the editorial commentary by Lalloo on pages 1760–2) Background. To our knowledge, to date, no p...
Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz ba...
Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in trea...
Background: Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant ...
Objective: The relationships between adverse events (AEs) and plasma concentrations of nevirapine (N...
<p>Comparison of median and inter quartile range of pre-treatment biochemical variables, liver chemi...
Background: The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiret...
AimsEfavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency vi...
Background: High-dose rifampicin is considered to shorten anti-TB treatment duration but its effect ...
<p>Comparison of efavirenz concentration between week 4 and week 16 with in Ethiopians and Tanzanian...
AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due ...
Efavirenz (EFV) is currently recommended by the international AIDS society as part of a combination ...
The aim of this study was to determine the utility of dried blood spots (DBS) compared with conventi...
INTRODUCTION: A recent report described a possible interaction between tenofovir (TFV) and efavirenz...
The steady-state pharmacokinetics of efavirenz and nevirapine, when used in combination to treat hum...
(See the editorial commentary by Lalloo on pages 1760–2) Background. To our knowledge, to date, no p...
Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz ba...
Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in trea...
Background: Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant ...
Objective: The relationships between adverse events (AEs) and plasma concentrations of nevirapine (N...
<p>Comparison of median and inter quartile range of pre-treatment biochemical variables, liver chemi...
Background: The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiret...
AimsEfavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency vi...
Background: High-dose rifampicin is considered to shorten anti-TB treatment duration but its effect ...
<p>Comparison of efavirenz concentration between week 4 and week 16 with in Ethiopians and Tanzanian...
AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due ...
Efavirenz (EFV) is currently recommended by the international AIDS society as part of a combination ...
The aim of this study was to determine the utility of dried blood spots (DBS) compared with conventi...
INTRODUCTION: A recent report described a possible interaction between tenofovir (TFV) and efavirenz...
The steady-state pharmacokinetics of efavirenz and nevirapine, when used in combination to treat hum...